Home Biosimilar Antibodies Protein Tyrosine Kinase VEGFR antibody Vulinacimab (Anti-VEGFR2 / KDR / CD309) For research use only.
Not for use in humans.

Vulinacimab (Anti-VEGFR2 / KDR / CD309)

Synonyms: HLX-06

Vulinacimab (Anti-VEGFR2 / KDR / CD309) is a monoclonal antibody targeting VEGFR-2. It has potential anti-angiogenesis and antineoplastic activities and can be used in the research of cancers. MW :145.38 KD.

Vulinacimab (Anti-VEGFR2 / KDR / CD309)

Purity & Quality Control

≥99

Choose Selective VEGFR Inhibitors

Biological Activity

Description Vulinacimab (Anti-VEGFR2 / KDR / CD309) is a monoclonal antibody targeting VEGFR-2. It has potential anti-angiogenesis and antineoplastic activities and can be used in the research of cancers. MW :145.38 KD.

Product Details

CAS No. 2250342-36-8
Isotype Human IgG1
Source CHO
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Vulinacimab (Anti-VEGFR2 / KDR / CD309) | Vulinacimab (Anti-VEGFR2 / KDR / CD309) supplier | purchase Vulinacimab (Anti-VEGFR2 / KDR / CD309) | Vulinacimab (Anti-VEGFR2 / KDR / CD309) cost | Vulinacimab (Anti-VEGFR2 / KDR / CD309) manufacturer | order Vulinacimab (Anti-VEGFR2 / KDR / CD309) | Vulinacimab (Anti-VEGFR2 / KDR / CD309) distributor